Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair
Affinity DataKi: <500nMAssay Description:The ability of the compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist SB222200 was assessed by an in vitro r...More data for this Ligand-Target Pair